Long-term effects of GLP-1 receptor agonists in type 2 diabetic patients: A retrospective real-life study in 131 patients

2019 ◽  
Vol 13 (1) ◽  
pp. 332-336 ◽  
Author(s):  
A. Hemmer ◽  
D. Maiter ◽  
M. Buysschaert ◽  
V. Preumont
Keyword(s):  
Real Life ◽  
Diabetic Patients ◽  
Long Term Effects ◽  
Type 2 Diabetic Patients ◽  
Life Study ◽  
Receptor Agonists ◽  
Real Life Study ◽  
Type 2 Diabetic

Long term effects of low protein diet on depressive symptoms and quality of life in elderly Type 2 diabetic patients

2012 ◽  
Vol 78 (08) ◽  
pp. 122-128 ◽  
Author(s):  
Tiziana Ciarambino ◽  
Pietro Castellino ◽  
Giuseppe Paolisso ◽  
Ludovico Coppola ◽  
Nicola Ferrara ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Depressive Symptoms ◽  
Diabetic Patients ◽  
Long Term Effects ◽  
Type 2 Diabetic Patients ◽  
Low Protein ◽  
Type 2 Diabetic

scholarly journals Dapagliflozin in the management of type 2 diabetes mellitus: a real-life experience in Bangladesh

2020 ◽  
Vol 11 (1) ◽  
pp. 57-62
Author(s):  
Mohammad Feroz Amin ◽  
Faria Afsana ◽  
Sultana Marufa Shefin ◽  
Shahjada Selim ◽  
Mahboob Ifhtekhar
Keyword(s):  
Type 2 Diabetes ◽  
Life Experience ◽  
Real Life ◽  
Diabetic Patients ◽  
Base Line ◽  
Open Label ◽  
Type 2 Diabetic Patients ◽  
Life Study ◽  
Type 2 Diabetic

Background: Dapagliflozin, a selective renal sodium-glucose cotransporter-2 inhibitor (SGLT2i), lowers plasma glucose by increasing urinary excretion of glucose. This study evaluated the efficacy and safety of dapagliflozin as add on therapy for a selected group of Bangladeshi type 2 diabetic patients. Methods: This was a 24-week, open-label, prospective, real-life study including type 2 diabetic patients with glycated hemoglobin (HbA1c) 7.0–10% (N =53). Study subjects were selectively assigned to dapagliflozin 5 mg once-daily in the morning along with ongoing oral anti-diabetic drug (OAD). The primary end point was to see the safety (adverse events) and efficacy (reduction of fasting and post-prandial blood glucose, HbA1c) of dapagliflozin. Results: Mean HbA1c changes from baseline to week 24 was – 1.15 ± 0.82 % (P = 0.000) and weight reduction was – 2.49 ± 0.32 kg from base line (P=0.000). Among total study subjects, 6 (11.3 %) had developed urinary tract infection (UTI). There were no major episodes of hypoglycemia or renal function deterioration. Conclusion: Dapagliflozin showed significant reduction of HbA1c as add on therapy. The low incidence of hypoglycemia and UTI make dapagliflozin as an acceptable addition to existing treatment option for type 2 diabetes in Bangladeshi population. Birdem Med J 2021; 11(1): 57-62

scholarly journals  -Cell Function in Severely Obese Type 2 Diabetic Patients: Long-term effects of bariatric surgery

Diabetes Care ◽  
2007 ◽  
Vol 30 (4) ◽  
pp. 1002-1004 ◽  
Author(s):  
S. Camastra ◽  
M. Manco ◽  
A. Mari ◽  
A. V. Greco ◽  
S. Frascerra ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Cell Function ◽  
Diabetic Patients ◽  
Long Term Effects ◽  
Type 2 Diabetic Patients ◽  
Severely Obese ◽  
Type 2 Diabetic
Sign in / Sign up

Export Citation Format

Share Document